1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98:1331–1334. PMID:
16985252.
2. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016; 387:894–906. PMID:
26318520.
3. Edge BE, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 3rd. AJCC cancer staging handbook: from the AJCC cancer staging mannual. 7th ed. Chicago (IL): Springer;2011.
4. Ramaswamy K, Kheterpal E, Pham H, Mohan S, Stifelman M, Taneja S, et al. Significance of pathologic T3a upstaging in clinical T1 renal masses undergoing nephrectomy. Clin Genitourin Cancer. 2015; 13:344–349. PMID:
25680295.
5. Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, et al. Pathological upstaging of clinical T1 to pathological T3a renal cell carcinoma: a multi-institutional analysis of short-term outcomes. Urology. 2016; 94:154–160. PMID:
27041471.
6. Mouracade P, Kara O, Dagenais J, Maurice MJ, Nelson RJ, Malkoc E, et al. Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors. World J Urol. 2017; 35:1425–1433. PMID:
28197727.
7. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005; 104:53–60. PMID:
15895375.
8. Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol. 2000; 24:451–458. PMID:
10716160.
9. Kim C, Choi HJ, Cho KS. Diagnostic value of multidetector computed tomography for renal sinus fat invasion in renal cell carcinoma patients. Eur J Radiol. 2014; 83:914–918. PMID:
24713489.
10. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008; 101:959–963. PMID:
18190639.
11. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol. 2013; 20:161–171. PMID:
22897628.
12. Han JH, Yoon YE, Kim SY, Cho YI, Rha KH, Choi YD, et al. Preoperative lymphocyte-monocyte ratio ameliorates the accuracy of differential diagnosis in non-metastatic infiltrative renal masses. Yonsei Med J. 2017; 58:388–394. PMID:
28120570.
13. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010; 184:873–878. PMID:
20643463.
14. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophilto-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013; 190:1999–2004. PMID:
23831313.
15. Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 2014; 32:1277–1284. PMID:
25017696.
16. Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumors in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009; 56:786–793. PMID:
19665284.
17. Bertini R, Roscigno M, Freschi M, Strada E, Petralia G, Pasta A, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol. 2009; 181:2027–2032. PMID:
19286201.
18. Koo KC, Kim JC, Cho KS, Choi YD, Hong SJ, Yang SC, et al. Oncological outcomes after partial vs radical nephrectomy in renal cell carcinomas of ≤7 cm with presumed renal sinus fat invasion on preoperative imaging. BJU Int. 2016; 117:87–93. PMID:
25099267.
19. Sokhi HK, Mok WY, Patel U. Stage T3a renal cell carcinoma: staging accuracy of CT for sinus fat, perinephric fat or renal vein invasion. Br J Radiol. 2015; 88:20140504. PMID:
25410425.
20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883–899. PMID:
20303878.
21. Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res. 2016; 4:83–91. PMID:
26839309.
22. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016; 16:599–611. PMID:
27526640.
23. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumors. Nat Rev Immunol. 2012; 12:253–268. PMID:
22437938.
24. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15:e493–e503. PMID:
25281468.
25. Sejima T, Iwamoto H, Morizane S, Hinata N, Yao A, Isoyama T, et al. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. Urol Oncol. 2013; 31:1343–1349. PMID:
22153754.
26. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013; 109:147–153. PMID:
23778526.
27. Koo KC, Lee KS, Cho KS, Rha KH, Hong SJ, Chung BH. Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. Int Urol Nephrol. 2016; 48:985–992. PMID:
26946137.